Efficacy of crizotinib in alectinib-refractory patients with NSCLC harboring EML4-ALK; phaseII trial (OLCSG1405)
Phase 2
- Conditions
- on-small cell lung cancer harboring EML4-ALK
- Registration Number
- JPRN-UMIN000015984
- Lead Sponsor
- Okayama Lung Cancer Study Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 9
Inclusion Criteria
Not provided
Exclusion Criteria
Patients with symptomatic brain metastases. Pregnant women, nursing mothers, the women who may be pregnant or have the will to get pregnant, and the men who hope for fertility with pregnancy. The patients with a history of hypersensitivity to crizotinib.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Objective response rate
- Secondary Outcome Measures
Name Time Method Progression-free survival, overall survival, expression of EML4-ALK and MET, adverse events, quality of life, and survey using the care notebook